AIM 

Clinical Investigation is dedicated to systematic coverage of the methodology, progress and outcomes of clinical trials and clinical research. Clinical Investigation is a peer-reviewed, monthly publication which provides a forum for the rapid publication of original research and critically reviews the latest developments in medical research, from Phase 1 trials through to post-marketing studies and pharmacoeconomic research.

SCOPE 

Clinical Investigation assimilates the wealth of information resulting from the clinical development of new medicines into concise yet comprehensive formats. The journal addresses contemporary issues in clinical drug development and methodology, and also provides a platform for the rapid publication of new drug data from human studies. Coverage spans all therapeutic areas and relates to conventional small-molecule drugs as well as biotech-derived therapeutic entities, including vaccines, monoclonal antibodies, antisense, cell and gene therapies and recombinant proteins, Clinical study design and methodology, Overviews of the clinical progress of new drugs or drug classes, Clinical progress for specific diseases or therapeutic areas, Findings in Phase I to IV clinical studies, Healthcare outcomes and pharmacoeconomics, Patient stratification and individualized therapies, Commentary on trials in progress, Drug safety issues and adverse event monitoring, Biomarkers in clinical trials, Regulatory issues, Clinical trial data management and statistics. The journal publishes review articles, original papers, perspectives, commentaries, meeting reports, news, views and more.

The topics covered but not limited to: